# T W I S T BIOSCIENCE

### Twist Bioscience Enhances Genes Product Offering with Longer Genes and Offers Access to Its Application Programming Interface

### January 7, 2019

SAN FRANCISCO-(BUSINESS WIRE)-Jan. 7, 2019- Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA, today announced it has expanded its product portfolio to offer genes up to five kilobases (5kb) in length at industry-leading pricing. In addition, Twist is making its Application Programming Interface (Twist API or TAPI) available for all customers ordering genes.

We are committed to continuously improving and expanding our product lines to serve more and more of our customers' needs." said Emily M. Leproust, Ph.D., CEO and co-founder of Twist. "For the last year, we have been supplying genes up to 5kb to Ginkgo Bloworks, and we are confident in our ability to precisely manufacture scalable quantities of these genes efficiently and clonal perfect. By offering long genes at the disruptive price of \$0.15 per base pair with a turnaround time between 15 and 25 days, we are continuing our efforts to increase our market share by converting DNA makers into DNA buyers."

### Twist Application Programming Interface (TAPI) Now Available for Gene Ordering

In addition to expanding its gene offering in length, Twist also announced the availability of the <u>Twist Accilication Programming Interface</u> (TAPI) for ordering synthetic genes, oligo pools and gene fragments. TAPI allows customers to integrate their internal software systems seamlessly with Twist's design and business systems. Importantly, TAPI offers the functionality of the Twist online ordering portal with sequence synthesis analysis, codon optimization, download of plate maps and a comprehensive order tracking process from order placed to shipment received. These features can save time and resources for customers.

"Once available only to our largest customers, we have opened up our TAPI for all customers interested in designing and building genes and their pathways in one step, while at the same time transferring data directly and securely," continued Dr. Leproust.

### About Clonal Perfect Synthetic Genes

Applying its proprietary DNA synthesis technology, Twist manufactures strands of DNA up to five kilobases (5kb) in length. Customers order synthetic genes to conduct a wide range of research, including product development for the healthcare, agricultural, and industrial industries as well as a multitude of applications within academic research. Virtually all research and development for the healthcare, agricultural, and industrial industries as well as a multitude of applications within academic research. Virtually all research and development requires trial and error, and institutions require many variations of genes to find the DNA sequence that achieves their objectives. Twist offers perfectly clonal genes in either Twist or customer vectors. For more information please click barge.

# About Twist Bioscience Corporation

Twist Bioscience is a leading and rapidly growing synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by "writing" DNA on a alicon chip. Twist is leveraping its indice to biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by "writing" DNA on a alicon chip. Twist is leveraping its unique technology to manufacture a broad range of synthetic DNA based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industrianis kindly multitaries including thereines, approximate and academic research.

## Follow us on Twitter | Facebook | LinkedIn | YouTube

To construct on the set of the se

View source version on businesswire.com: https://www.businesswire.com/news/home/20190107005466/en/

Source: Twist Bioscience Corporation Investor Contact: Argot Partners Maeve Conneighton 212-600-1902 maeve@argotpartners.com Media Contact:

Media Contact: Angela Bitting 925-202-6211